

Recombinant Human PAK3 Protein (His Tag)

Catalog Number: PKSH030366

Note: Centrifuge before opening to ensure complete recovery of vial contents.


Description

Species	Human
Source	Baculovirus-Insect Cells-derived Human PAK3 protein Met 1-Arg 544, with an C-terminal His
Calculated MW	62.0 kDa
Observed MW	60 kDa
Accession	O75914-2
Bio-activity	The specific activity was determined to be 98 nmol/min/mg using MBP as substrate.

Properties

Purity	> 80 % as determined by reducing SDS-PAGE.
Concentration	Subject to label value.
Endotoxin	< 1.0 EU per µg of the protein as determined by the LAL method.
Storage	Store at < -20°C, stable for 6 months. Please minimize freeze-thaw cycles.
Shipping	This product is provided as liquid. It is shipped at frozen temperature with blue ice/ gel packs. Upon receipt, store it immediately at < - 20°C.
Formulation	Supplied as sterile solution of 20mM Tris, 500mM NaCl, pH 7.4, 10% glycerol

Data



> 80 % as determined by reducing SDS-PAGE.

Background

PAK3 is a member of PAK proteins, a family of serine/threonine p21-activating kinases, serve as effectors of small Rho GTPases Cdc42 and RAC and have been implicated in a wide range of biological activities. There are six mammalian PAKs which can be divided into two groups: group I PAKs (PAK1-3) and group II PAKs (PAK4-6). Although the two PAK groups are architecturally similar there are differences in their mode of regulation suggesting their cellular functions are likely to be different. Group I p21-activated kinases (PAK1/2/3) is demonstrated as ERK3/ERK4 activation loop kinases. It has been shown that group I PAKs phosphorylate ERK3 and ERK4 on Ser-189 and Ser-186, respectively, both in vitro and in vivo, and that expression of activated Rac1 augments this response. Besides regulation enzymatic activation of ERK3/ERK4, PAKs can also play roles in downstream activation of MAP kinase-activated protein kinase 5 (MK5) in vivo. Thus, the group I PAKs act as upstream activators of ERK3 and ERK4 and unravel a novel PAK-ERK3/ERK4-MK5 signaling pathway. In clinical, PAK has been proposed as a potential therapeutic target in schwannomas.

For Research Use Only